Login to Your Account

NeuroSearch's Shares Plunge As NS2330 Fails In Three Trials

By Cormac Sheridan

Wednesday, August 17, 2005
NeuroSearch's shares crashed more than 40 percent Aug. 10 on news that its lead drug candidate, NS2330, failed to achieve efficacy in two Phase IIb trials for Parkinson's disease and a third Phase IIb trial for Alzheimer's disease, dashing hopes that the compound would move into Phase III. (BioWorld International)

To continue reading subscribe now to BioWorld Asia (formerly International)

Learn More about BioWorld Asia (formerly International)

Already a subscriber? Sign In or Buy now to activate your subscription